Acromegaly medical therapy

Jump to navigation Jump to search

Acromegaly Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acromegaly from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Radiation Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acromegaly medical therapy On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acromegaly medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acromegaly medical therapy

CDC on Acromegaly medical therapy

Acromegaly medical therapy in the news

Blogs on Acromegaly medical therapy

Directions to Hospitals Treating Acromegaly

Risk calculators and risk factors for Acromegaly medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Patients with acromegaly are treated with somatostatin analogs like octreotide, dopamine agonists like bromocriptine, and GH receptor antagonist like pegvisomant. Radiation therapy is indicated in patients who do not respond to surgery or the medical therapy.

Medical Therapy

  • Pharmacologic medical therapy is recommended among patients with persistent high growth hormone level after the surgery.[1]
  • Pharmacologic medical therapies for acromegaly include somatostatin analogs, dopamine agonists, and GH receptor antagonists.

Different treatment regimens

  • 1.1.1 Somatostatin analogs:
    • Preferred regimen (1): Octreotide 50 mcg q8hr subcutaneous as initial dose and 100 mcg q8hr as effective dose.
    • Preferred regimen (2): Lanreotide 90 mg q4week for 3 months every 4 weeks subcutaneous.
    • Preferred regimen (3): Pasireotide 40 mg q4wk intramuscular.
  • 1.1.2 Dopamine agonists:
    • Preferred regimen (1): Cabergoline 0.25 mg 2x/week orally.
    • Preferred regimen (2): Bromocriptine 1.25-2.5 mg qDay orally.
  • 1.1.3 GH receptor antagonist:
    • Preferred regimen (1): Pegvisomant 10 mg qDay subcutaneous.

Radiation therapy

  • Radiation therapy is indicated in the patients that still have an excess level of GH and IGF-1 after surgery and medical therapy. It is also indicated in patients who still have tumor remaining after surgery.
  • It is recommended by the endocrine society to use the stereotactic radiotherapy (SRT) over conventional radiation in the treatment of the acromegaly.
  • Follow up with the level of the GH and IGF-1 annually to determine the efficacy of the radiation in the treatment of acromegaly.

References

  1. Katznelson L, Laws ER, Melmed S, Molitch ME, Murad MH, Utz A; et al. (2014). "Acromegaly: an endocrine society clinical practice guideline". J Clin Endocrinol Metab. 99 (11): 3933–51. doi:10.1210/jc.2014-2700. PMID 25356808.

Template:WH Template:WS